Literature DB >> 31591195

Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer's molecular signatures.

Abhijeet Sharma1,2,3, Syed Faraz Kazim1,2,3, Chloe S Larson1,2,3,4, Aarthi Ramakrishnan2,3, Jason D Gray4, Bruce S McEwen5, Paul A Rosenberg6,7, Li Shen2,3, Ana C Pereira8,2,3.   

Abstract

The excitatory amino acid transporter 2 (EAAT2) is the major glutamate transporter in the brain expressed predominantly in astrocytes and at low levels in neurons and axonal terminals. EAAT2 expression is reduced in aging and sporadic Alzheimer's disease (AD) patients' brains. The role EAAT2 plays in cognitive aging and its associated mechanisms remains largely unknown. Here, we show that conditional deletion of astrocytic and neuronal EAAT2 results in age-related cognitive deficits. Astrocytic, but not neuronal EAAT2, deletion leads to early deficits in short-term memory and in spatial reference learning and long-term memory. Neuronal EAAT2 loss results in late-onset spatial reference long-term memory deficit. Neuronal EAAT2 deletion leads to dysregulation of the kynurenine pathway, and astrocytic EAAT2 deficiency results in dysfunction of innate and adaptive immune pathways, which correlate with cognitive decline. Astrocytic EAAT2 deficiency also shows transcriptomic overlaps with human aging and AD. Overall, the present study shows that in addition to the widely recognized astrocytic EAAT2, neuronal EAAT2 plays a role in hippocampus-dependent memory. Furthermore, the gene expression profiles associated with astrocytic and neuronal EAAT2 deletion are substantially different, with the former associated with inflammation and synaptic function similar to changes observed in human AD and gene expression changes associated with inflammation similar to the aging human brain.

Entities:  

Keywords:  Alzheimer’s disease; aging; glutamate transporter

Year:  2019        PMID: 31591195      PMCID: PMC6815169          DOI: 10.1073/pnas.1903566116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  102 in total

1.  GLT-1 loss accelerates cognitive deficit onset in an Alzheimer's disease animal model.

Authors:  Paramita Mookherjee; Pattie S Green; G Stennis Watson; Marcos A Marques; Kohichi Tanaka; Kole D Meeker; James S Meabon; Ning Li; Ping Zhu; Valerie G Olson; David G Cook
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 2.  Neuron numbers and dendritic extent in normal aging and Alzheimer's disease.

Authors:  P D Coleman; D G Flood
Journal:  Neurobiol Aging       Date:  1987 Nov-Dec       Impact factor: 4.673

3.  Behavioral phenotyping and dopamine dynamics in mice with conditional deletion of the glutamate transporter GLT-1 in neurons: resistance to the acute locomotor effects of amphetamine.

Authors:  Kathryn D Fischer; Alex C W Houston; Rajeev I Desai; Michelle R Doyle; Jack Bergman; Maha Mian; Rebekah Mannix; David L Sulzer; Se Joon Choi; Eugene V Mosharov; Nathaniel W Hodgson; Anita Bechtholt; Klaus A Miczek; Paul A Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  2018-02-22       Impact factor: 4.530

4.  Relationship between increase in astrocytic GLT-1 glutamate transport and late-LTP.

Authors:  Juan D Pita-Almenar; Shengwei Zou; Costa M Colbert; Arnold Eskin
Journal:  Learn Mem       Date:  2012-11-19       Impact factor: 2.460

Review 5.  Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease.

Authors:  John H Morrison; Patrick R Hof
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

6.  Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss.

Authors:  Maria Talantova; Sara Sanz-Blasco; Xiaofei Zhang; Peng Xia; Mohd Waseem Akhtar; Shu-ichi Okamoto; Gustavo Dziewczapolski; Tomohiro Nakamura; Gang Cao; Alexander E Pratt; Yeon-Joo Kang; Shichun Tu; Elena Molokanova; Scott R McKercher; Samuel Andrew Hires; Hagit Sason; David G Stouffer; Matthew W Buczynski; James P Solomon; Sarah Michael; Evan T Powers; Jeffery W Kelly; Amanda Roberts; Gary Tong; Traci Fang-Newmeyer; James Parker; Emily A Holland; Dongxian Zhang; Nobuki Nakanishi; H-S Vincent Chen; Herman Wolosker; Yuqiang Wang; Loren H Parsons; Rajesh Ambasudhan; Eliezer Masliah; Stephen F Heinemann; Juan C Piña-Crespo; Stuart A Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

7.  The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function.

Authors:  Samuel E Marsh; Edsel M Abud; Anita Lakatos; Alborz Karimzadeh; Stephen T Yeung; Hayk Davtyan; Gianna M Fote; Lydia Lau; Jason G Weinger; Thomas E Lane; Matthew A Inlay; Wayne W Poon; Mathew Blurton-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-16       Impact factor: 11.205

8.  Method and validation of synaptosomal preparation for isolation of synaptic membrane proteins from rat brain.

Authors:  Pradip Kumar Kamat; Anuradha Kalani; Neetu Tyagi
Journal:  MethodsX       Date:  2014

Review 9.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.

Authors:  Giles E Hardingham; Hilmar Bading
Journal:  Nat Rev Neurosci       Date:  2010-09-15       Impact factor: 34.870

Review 10.  Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation.

Authors:  Michal Schwartz; Kuti Baruch
Journal:  J Autoimmun       Date:  2014-09-08       Impact factor: 7.094

View more
  17 in total

1.  Estimating the glutamate transporter surface density in distinct sub-cellular compartments of mouse hippocampal astrocytes.

Authors:  Anca R Rǎdulescu; Gabrielle C Todd; Cassandra L Williams; Benjamin A Bennink; Alex A Lemus; Haley E Chesbro; Justin R Bourgeois; Ashley M Kopec; Damian G Zuloaga; Annalisa Scimemi
Journal:  PLoS Comput Biol       Date:  2022-02-04       Impact factor: 4.475

2.  Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Methods Mol Biol       Date:  2022

3.  Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease.

Authors:  Ludovica Iovino; Veronica Giusti; Francesca Pischedda; Elena Giusto; Nicoletta Plotegher; Antonella Marte; Ilaria Battisti; Angela Di Iacovo; Algerta Marku; Giovanni Piccoli; Rina Bandopadhyay; Carla Perego; Tiziana Bonifacino; Giambattista Bonanno; Cristina Roseti; Elena Bossi; Giorgio Arrigoni; Luigi Bubacco; Elisa Greggio; Sabine Hilfiker; Laura Civiero
Journal:  Acta Neuropathol       Date:  2022-05-21       Impact factor: 15.887

Review 4.  Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease.

Authors:  Shampa Ghosh; Shantanu Durgvanshi; Shreya Agarwal; Manchala Raghunath; Jitendra Kumar Sinha
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 5.  Regulation of Glutamate, GABA and Dopamine Transporter Uptake, Surface Mobility and Expression.

Authors:  Renae M Ryan; Susan L Ingram; Annalisa Scimemi
Journal:  Front Cell Neurosci       Date:  2021-04-13       Impact factor: 5.505

6.  Methamphetamine Activates Trace Amine Associated Receptor 1 to Regulate Astrocyte Excitatory Amino Acid Transporter-2 via Differential CREB Phosphorylation During HIV-Associated Neurocognitive Disorders.

Authors:  Irma E Cisneros; Anuja Ghorpade; Kathleen Borgmann
Journal:  Front Neurol       Date:  2020-11-25       Impact factor: 4.003

7.  Differential Proteomic Analysis of the Hippocampus in Rats with Neuropathic Pain to Investigate the Use of Electroacupuncture in Relieving Mechanical Allodynia and Cognitive Decline.

Authors:  Degui Gong; Xiangmei Yu; Menghong Jiang; Changzheng Li; Zhifu Wang
Journal:  Neural Plast       Date:  2021-08-04       Impact factor: 3.599

8.  Neuronal Loss of the Glutamate Transporter GLT-1 Promotes Excitotoxic Injury in the Hippocampus.

Authors:  Theresa S Rimmele; Shaomin Li; Jens Velde Andersen; Emil W Westi; Alexander Rotenberg; Jianlin Wang; Blanca Irene Aldana; Dennis J Selkoe; Chiye J Aoki; Chris G Dulla; Paul Allen Rosenberg
Journal:  Front Cell Neurosci       Date:  2021-12-29       Impact factor: 5.505

9.  Chronic Intermittent Hypoxia Enhances Pathological Tau Seeding, Propagation, and Accumulation and Exacerbates Alzheimer-like Memory and Synaptic Plasticity Deficits and Molecular Signatures.

Authors:  Syed Faraz Kazim; Abhijeet Sharma; Sivaprakasam R Saroja; Joon Ho Seo; Chloe S Larson; Aarthi Ramakrishnan; Minghui Wang; Robert D Blitzer; Li Shen; Catherine J Peña; John F Crary; Larissa A Shimoda; Bin Zhang; Eric J Nestler; Ana C Pereira
Journal:  Biol Psychiatry       Date:  2021-03-24       Impact factor: 13.382

10.  Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease.

Authors:  Dawn C Matthews; Xiangling Mao; Kathleen Dowd; Diamanto Tsakanikas; Caroline S Jiang; Caroline Meuser; Randolph D Andrews; Ana S Lukic; Jihyun Lee; Nicholas Hampilos; Neeva Shafiian; Mary Sano; P David Mozley; Howard Fillit; Bruce S McEwen; Dikoma C Shungu; Ana C Pereira
Journal:  Brain       Date:  2021-12-31       Impact factor: 15.255

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.